What were the key takeaways from Mayne Pharma’s (ASX:MYX) Q3 FY26 results?

Mayne Pharma reported a 1% revenue increase to $85.2 million and a significant 57% improvement in underlying EBITDA. The result was driven by the successful launch of the DistributeRx platform and strong growth in the Women’s Health portfolio.

How did the DistributeRx launch impact Mayne Pharma (ASX:MYX)?

The DistributeRx platform significantly outperformed expectations, with initial prescription demand coming in 72% ahead of internal forecasts. This launch is a core part of management’s "disintermediation strategy," aimed at streamlining how products reach patients.

Is Mayne Pharma (ASX:MYX) profitable after the Q3 FY26 update?

Mayne Pharma is not yet profitable on a statutory basis, reporting a net loss after tax (NPAT) of $21 million for the quarter. However, the loss narrowed compared to the $22.5 million loss in the previous corresponding period.

What drove the growth in Mayne Pharma’s Women’s Health and Dermatology segments?

The Women’s Health portfolio saw double-digit growth, with BIJUVA® prescriptions up 30% and NEXTSTELLIS® demand cycles up 12% compared to last year. Meanwhile, the Dermatology segment saw a 43% jump in direct contribution.

How strong is Mayne Pharma’s (ASX:MYX) balance sheet and cash position?

Mayne Pharma’s liquidity is a highlight of this report, with $86.7 million in cash and marketable securities as of 31 March 2026. Adjusted operating cash flow from continuing operations surged 90% to $28.3 million.

What are the main bull and bear points for Mayne Pharma (ASX:MYX) investors?

The bull case rests on the 90% surge in operating cash flow and the massive outperformance of the DistributeRx launch. The bear case is centred on the fact that the company remains loss-making at the bottom line despite these operational wins.

Did US trade policy or tariffs affect Mayne Pharma’s (ASX:MYX) earnings?

Despite concerns regarding the US tariff proclamation on 7 April, Mayne Pharma confirmed there has been no material earnings impact on the business. This is a crucial update for retail traders, as many pharmaceutical companies with US exposure faced speculative selling leading up to the proclamation.

Mayne Pharma gains momentum as DistributeRx launches strong

Written by Liezl GambePublished Apr. 29 2026Last Updated Apr. 29 2026

Mayne Pharma (ASX:MYX) recorded a rise in commercial momentum for the third quarter of FY26, underpinned by the high-impact launch of its DistributeRx platform.

The Adelaide-based pharmaceutical company revealed that DistributeRx achieved prescription demand 72% ahead of internal forecasts within its first month.

The rollout, alongside double-digit growth in its Women’s Health portfolio—specifically BIJUVA® (up 30%) and NEXTSTELLIS® (up 12%)—has bolstered the company’s market position despite broader economic headwinds.

Financially, Mayne Pharma reported a 1% increase in revenue to $85.2 million compared to the previous corresponding period.

While the company recorded a statutory net loss after tax of $21 million, key underlying metrics showed significant year-on-year improvement.

Underlying EBITDA rose by 57% to a loss of $1.4 million, driven largely by a 43% contribution jump from the dermatology segment.

The most striking figure in the report was the company's cash performance. Adjusted operating cash flow from continuing operations soared by 90% to $28.3 million.

As of March 31, Mayne Pharma maintains a robust liquidity position with $86.7 million in cash and marketable securities.

CEO Aaron Gray noted that the company’s "disintermediation strategy" is now delivering tangible results, aided by favourable regulatory shifts from the FDA regarding hormone therapy labelling.

At the time of reporting, Mayne Pharma’s share price was $2.79.